Welcome to our dedicated page for Definitive Healthcare news (Ticker: DH), a resource for investors and traders seeking the latest updates and insights on Definitive Healthcare stock.
About Definitive Healthcare Corp. (DH)
Definitive Healthcare Corp. (Nasdaq: DH) is a leading provider of healthcare commercial intelligence, delivering actionable data and insights to organizations across the healthcare ecosystem. The company's mission is to transform data, analytics, and expertise into meaningful intelligence that enables its clients to uncover opportunities, optimize strategies, and drive growth. By leveraging a robust SaaS-based platform, Definitive Healthcare empowers clients to navigate the complexities of the healthcare market with precision and confidence.
Comprehensive Data and Analytics Platform
At the core of Definitive Healthcare's offerings is its proprietary platform, which aggregates and analyzes data on over 8,100 hospitals, 7,300 ambulatory surgery centers, 11,000 imaging centers, 38,000 long-term care facilities, 1,200 accountable care organizations (ACOs) and health information exchanges (HIEs), 197,000 physician groups, 1.3 million physicians, and 750 Canadian hospitals. This extensive dataset provides clients with unparalleled visibility into the healthcare provider landscape, enabling them to make informed decisions in areas such as market segmentation, sales execution, and product development.
Key Solutions and Products
- Monocl ExpertInsight: A comprehensive tool that delivers data on more than 15 million medical experts globally, helping pharmaceutical and medtech companies enhance Key Opinion Leader (KOL) engagement and clinical collaboration.
- Population Intelligence: Combines clinical and consumer data to enable precision marketing, allowing businesses to identify and target specific audience segments effectively.
- Carevoyance: A solution tailored for medtech sales teams, providing deep insights into provider segmentation, territory alignment, and sales tracking to streamline workflows and accelerate device adoption.
- Market Forecast: A predictive analytics tool that offers three, five, and ten-year market trend projections, helping healthcare organizations plan strategically for future demand and growth opportunities.
- DH View Suite: A mobile-enabled platform that equips sales and marketing teams with instant access to critical intelligence on healthcare professionals and organizations, enhancing productivity and client engagement.
- Monocl Conferences: A specialized solution for life sciences organizations to optimize conference planning and participation, providing insights into key presentations, trending topics, and expert engagement opportunities.
Market Position and Competitive Landscape
Operating within the rapidly evolving healthcare data analytics industry, Definitive Healthcare stands out for its depth of data, innovative solutions, and focus on healthcare-specific use cases. Its competitors include companies like IQVIA and Truveta, but Definitive Healthcare differentiates itself through its tailored SaaS offerings and the integration of predictive analytics with real-time data visualization. The company's solutions address critical challenges faced by healthcare organizations, such as identifying high-growth markets, optimizing sales territories, and enhancing patient engagement strategies.
Revenue Model and Geographic Focus
Definitive Healthcare generates the majority of its revenue through subscription-based services, offering scalable solutions that cater to organizations of all sizes. While its primary market is the United States, the company also provides data on international healthcare providers, particularly in Canada, further broadening its client base and market reach.
Challenges and Opportunities
As a data-centric organization, Definitive Healthcare faces challenges such as ensuring the accuracy and comprehensiveness of its datasets, navigating complex regulatory environments, and mitigating cybersecurity risks. However, its investments in proprietary data science, AI-driven analytics, and user-friendly interfaces position it well to address these challenges and capitalize on growing demand for healthcare intelligence solutions.
Conclusion
Definitive Healthcare Corp. is a pivotal player in the healthcare commercial intelligence space, enabling organizations to unlock new opportunities and optimize their operations through data-driven insights. With its diverse product portfolio, deep industry expertise, and commitment to innovation, Definitive Healthcare continues to shape the future of the healthcare market, providing clients with the tools they need to succeed in an increasingly competitive landscape.
Definitive Healthcare Corp. (Nasdaq: DH) announced that CEO Jason Krantz and CFO Rick Booth will present at the J.P. Morgan 50th Annual Global Technology, Media and Communications Conference. The presentation is scheduled for May 23, 2022, at 9:20 a.m. Eastern Time. A live webcast will be accessible through their investor relations website, with a replay available for a limited time. Definitive Healthcare specializes in healthcare commercial intelligence, providing clients insights to drive success in the healthcare market.
Definitive Healthcare Corp. (Nasdaq: DH) reported a 36% year-over-year increase in first-quarter revenue, reaching $50.1 million compared to $36.9 million in Q1 2021. Despite a net loss of ($13.1) million, which is 26% of revenue, the company showed strong operational cash flow at $13.6 million, or 27% of revenue. Adjusted net income rose to $7.7 million, highlighting profitability amidst growth. Looking ahead, the company forecasts Q2 2022 revenue between $53.0 - $54.0 million, indicating continued momentum.
Definitive Healthcare Corp. (Nasdaq: DH) announced the appointment of Robert Musslewhite as the new CEO, effective August 1, 2022. Founder Jason Krantz will transition to Executive Chairman but will remain involved in the company's strategic direction. Musslewhite, previously President, has a strong SaaS and healthcare background, including experience as CEO at OptumInsight and The Advisory Board Company. He aims to leverage his expertise to further advance the company's growth. Definitive Healthcare emphasizes its commitment to healthcare commercial intelligence with nearly 3,000 customers.
Definitive Healthcare Corp. (Nasdaq: DH) announced that it will release its first quarter financial results for the period ending March 31, 2022, on May 5, 2022, after market close. A conference call and webcast will be held at 4:30 PM ET to discuss these results. Interested parties can access the audio webcast on Definitive Healthcare's Investor Relations website. A replay of the call will be available until May 19, 2022, using the provided dial-in numbers.
Definitive Healthcare (Nasdaq: DH) has launched the Passport Analytics Suite, designed to enhance the efficiency of life sciences organizations in product development and commercialization. Powered by technologies from the recently acquired Analytical Wizards, the suite includes Passport Promotional Analytics and Passport Planning & Performance. These tools enable clients to optimize brand performance, marketing strategies, and product planning by integrating diverse data sources. This innovation positions Definitive Healthcare as a leader in offering comprehensive, data-agnostic analytics solutions.
Definitive Healthcare Corp. (Nasdaq: DH) has announced its participation in two key conferences in March 2022. The company will present at the Raymond James 43rd Annual Institutional Investors Conference on March 7 at 1:05 PM ET, featuring CEO Jason Krantz and CFO Rick Booth. Additionally, they will present at the Deutsche Bank 30th Annual Media, Internet & Telecom Conference on March 14 at 10:20 AM ET, with President Robert Musslewhite and CFO Booth. Both events will be webcast live, with replays available later.
Definitive Healthcare reported a 38% increase in Q4 2021 revenue to $46.3 million, while full-year revenue grew 40% to $166.2 million. Despite a GAAP net loss of $(14.8) million in Q4, adjusted net income rose to $6.6 million. Adjusted EBITDA in Q4 was $13.1 million, or 28% of revenue. For 2022, the company projects revenue between $218 million and $222 million. Key highlights include significant new contracts with major healthcare companies and the launch of a new product, Latitude Reporting.
Definitive Healthcare (Nasdaq: DH) will report its Q4 and full year 2021 financial results on February 23, 2022, post-market close. The company will also host a conference call and webcast at 5:00 PM ET to discuss these results. Investors can access the live audio webcast via the Investor Relations website. A replay of the call will be available shortly after its conclusion and will remain accessible until March 9, 2022. Definitive Healthcare specializes in healthcare commercial intelligence, leveraging data and analytics for market success.
Definitive Healthcare (Nasdaq: DH) launched Latitude Discovery on January 25, 2022, aimed at aiding pre-commercial biopharma and medical device companies. This innovative tool allows users to perform iterative analyses of real-world data to evaluate market opportunities linked to therapy development. Latitude Discovery provides self-service access to extensive market intelligence, enabling efficient cohort creation and real-time commercial intelligence visualizations. This product is part of the Latitude Analytics Suite, enhancing companies' commercialization efforts with precise analytics.
FAQ
What is the current stock price of Definitive Healthcare (DH)?
What is the market cap of Definitive Healthcare (DH)?
What does Definitive Healthcare Corp. do?
What industries does Definitive Healthcare serve?
How does Definitive Healthcare generate revenue?
What are some of Definitive Healthcare's key products?
What makes Definitive Healthcare unique in its industry?
Who are Definitive Healthcare's competitors?
What challenges does Definitive Healthcare face?
What geographic regions does Definitive Healthcare cover?
What is Monocl ExpertInsight?
How does Population Intelligence benefit businesses?
